[{"address1": "20 Commerce Drive", "address2": "Suite 135", "city": "Cranford", "state": "NJ", "zip": "07016", "country": "United States", "phone": "732 980 4500", "website": "https://www.enzon.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Enzon Pharmaceuticals, Inc., together with its subsidiaries, engages in marketing drug products. The company's marketed drug product is PegIntron. It also has a marketing agreement relating to Vicineum drug. The company was founded in 1981 and is headquartered in Cranford, New Jersey.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Richard L. Feinstein", "age": 80, "title": "CEO, CFO & Company Secretary", "yearBorn": 1943, "fiscalYear": 2022, "totalPay": 209452, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 0.0797, "open": 0.09109, "dayLow": 0.0712, "dayHigh": 0.0997, "regularMarketPreviousClose": 0.0797, "regularMarketOpen": 0.09109, "regularMarketDayLow": 0.0712, "regularMarketDayHigh": 0.0997, "exDividendDate": 1569801600, "beta": 0.273, "trailingPE": "Infinity", "volume": 28638, "regularMarketVolume": 28638, "averageVolume": 17667, "averageVolume10days": 6510, "averageDailyVolume10Day": 6510, "bid": 0.38, "ask": 1.41, "bidSize": 3000, "askSize": 200, "marketCap": 6853718, "fiftyTwoWeekLow": 0.06, "fiftyTwoWeekHigh": 0.23, "fiftyDayAverage": 0.0824, "twoHundredDayAverage": 0.12615, "currency": "USD", "enterpriseValue": 2484280, "floatShares": 30114059, "sharesOutstanding": 74214600, "sharesShort": 259381, "sharesShortPriorMonth": 298381, "sharesShortPreviousMonthDate": 1460678400, "dateShortInterest": 1463097600, "sharesPercentSharesOut": 0.0058999998, "heldPercentInsiders": 0.108389996, "heldPercentInstitutions": 0.48584, "shortRatio": 1.71, "shortPercentOfFloat": 0.0068, "impliedSharesOutstanding": 74214600, "bookValue": 0.047, "priceToBook": 1.9648937, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "earningsQuarterlyGrowth": 1.018, "netIncomeToCommon": 98000, "52WeekChange": -0.57142854, "SandP52WeekChange": 0.27320957, "lastDividendValue": 0.12, "lastDividendDate": 1569801600, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "ENZN", "underlyingSymbol": "ENZN", "shortName": "ENZON PHARMACEUTICALS INC", "longName": "Enzon Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 445703400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "0587b8b7-aa7f-39dd-a561-8adfc18ffdbb", "messageBoardId": "finmb_269599", "gmtOffSetMilliseconds": -14400000, "currentPrice": 0.09235, "recommendationKey": "none", "totalCash": 47012000, "totalCashPerShare": 0.633, "quickRatio": 27.428, "currentRatio": 27.621, "returnOnAssets": -0.0136899995, "returnOnEquity": 0.02989, "freeCashflow": -563500, "operatingCashflow": 1305000, "earningsGrowth": 0.291, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-10"}]